Retinitis Pigmentosa clinical trials
20 active trials name this condition. Describe your situation to see which ones look like a fit.
By location
- BS01 in Patients With Retinitis Pigmentosa
- A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa
- The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
- Stem Cell Ophthalmology Treatment Study II
- A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)
- Study of BEST1 Vitelliform Macular Dystrophy
- Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants
- Retinal Imaging in Patients With Inherited Retinal Degenerations
- Rod and Cone Mediated Function in Retinal Disease
- Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)
- Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration
- Adaptive Optics Imaging of Outer Retinal Diseases
- Inherited Retinal Degenerative Disease Registry
- High Resolution Retinal Imaging
- Cell Collection to Study Eye Diseases
- Experimental and Clinical Studies of Retinal Stimulation
- Promising ROd-cone DYstrophy Gene therapY
- A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001
- Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
- Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Retinitis Pigmentosa” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.